, Res Pract Thromb Haemost, 2019.

A. H. Charafeddine, E. J. Kim, D. M. Maynard, H. Yi, T. A. Weaver et al., Platelet-derived CD154: ultrastructural localization and clinical correlation in organ transplantation, Am J Transplant, vol.12, pp.3143-51, 2012.

J. Kamykowski, P. Carlton, S. Sehgal, and B. Storrie, Quantitative immunofluorescence mapping reveals little functional coclustering of proteins within platelet alpha-granules, Blood, vol.118, pp.1370-1373, 2011.

P. Aukrust, F. Muller, T. Ueland, T. Berget, E. Aaser et al., Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes, Circulation, vol.100, pp.614-634, 1999.

V. Henn, S. Steinbach, K. Buchner, P. Presek, and R. A. Kroczek, The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40, Blood, vol.98, pp.1047-54, 2001.

A. Hermann, B. H. Rauch, M. Braun, K. Schror, and A. A. Weber, Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel, Platelets, vol.12, pp.74-82, 2001.

Y. Jin, S. Nonoyama, T. Morio, K. Imai, H. D. Ochs et al., Characterization of soluble CD40 ligand released from human activated platelets, J Med Dent Sci, vol.48, pp.23-30, 2001.

L. Nannizzi-alaimo, M. H. Rubenstein, V. L. Alves, G. Y. Leong, D. R. Phillips et al., Cardiopulmonary bypass induces release of soluble CD40 ligand, Circulation, vol.105, pp.2849-54, 2002.

K. Otterdal, T. M. Pedersen, and N. O. Solum, Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase, Thromb Res, vol.114, pp.167-77, 2004.

P. Andre, L. Nannizzi-alaimo, S. K. Prasad, and D. R. Phillips, Platelet-derived CD40L: the switch-hitting player of cardiovascular disease, Circulation, vol.106, pp.896-905, 2002.

P. Andre, K. S. Prasad, C. V. Denis, M. He, J. M. Papalia et al., CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism, Nat Med, vol.8, pp.247-52, 2002.

K. S. Prasad, P. Andre, M. He, M. Bao, J. Manganello et al., Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling, Proc Natl Acad Sci, vol.100, pp.12367-71, 2003.

A. R. Crow, V. Leytin, A. F. Starkey, M. L. Rand, and A. H. Lazarus, CD154 (CD40 ligand)-deficient mice exhibit prolonged bleeding time and decreased shear-induced platelet aggregates, J Thromb Haemost, vol.1, pp.850-852, 2003.

M. Hausding, K. Jurk, S. Daub, S. Kroller-schon, J. Stein et al., CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction, Basic Res Cardiol, vol.108, p.386, 2013.

M. Iannacone, G. Sitia, M. Isogawa, J. K. Whitmire, P. Marchese et al., Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus, Proc Natl Acad Sci U S A, vol.105, pp.629-663, 2008.

X. F. Lin, X. L. Ten, X. B. Tang, and J. Chen, Serum soluble CD40 ligand levels after acute intracerebral hemorrhage, Acta Neurol Scand, vol.133, pp.192-201, 2016.

A. Dewitte, A. Tanga, J. Villeneuve, S. Lepreux, A. Ouattara et al., New frontiers for platelet CD154, Exp Hematol Oncol, vol.4, p.6, 2015.

T. Cuisset, G. Cayla, C. Frere, J. Quilici, R. Poyet et al., Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment, EuroIntervention, vol.5, pp.325-334, 2009.

D. Sibbing, S. Schulz, S. Braun, T. Morath, J. Stegherr et al., Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement, J Thromb Haemost, vol.8, pp.250-256, 2010.

T. Cuisset, M. Loosveld, P. E. Morange, J. Quilici, P. J. Moro et al., CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome, JACC Cardiovasc Interv, vol.5, pp.1280-1287, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00771418

G. Parodi, B. Bellandi, F. Venditti, N. Carrabba, R. Valenti et al., Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel, Am J Cardiol, vol.109, pp.214-222, 2012.

K. I. Kalantzi, A. A. Dimitriou, J. A. Goudevenos, and A. D. Tselepis, The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment, Platelets, vol.23, pp.121-152, 2012.

J. Saw, E. H. Madsen, S. Chan, and E. Maurer-spurej, The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study, J Am Coll Cardiol, vol.52, pp.1826-1859, 2008.

V. L. Serebruany, M. G. Midei, H. Meilman, A. I. Malinin, and D. R. Lowry, Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study, Postgrad Med J, vol.82, pp.404-414, 2006.

J. V. Mitsios, A. I. Papathanasiou, M. Elisaf, J. A. Goudevenos, and A. D. Tselepis, The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes, Platelets, vol.16, pp.287-92, 2005.

J. Y. Kim, K. Lee, M. Shin, M. Ahn, H. Choe et al., Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention, Circ J, vol.71, pp.1867-72, 2007.

P. Osmancik, P. Paulu, P. Tousek, V. Kocka, and P. Widimsky, High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel, J Thromb Thrombolysis, vol.33, pp.349-54, 2012.

S. Solheim, A. A. Pettersen, H. Arnesen, and I. Seljeflot, No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease, Thromb Haemost, vol.96, pp.660-664, 2006.

C. Stellbaum, T. Willich, U. Boltzen, Y. Ayral, B. Szotowski et al., Clopidogrel-mediated reduction of circulating tissue factor in patients with stable coronary artery disease, Eur J Haematol, vol.78, pp.347-52, 2007.

H. K. Yip, L. T. Chang, C. K. Sun, C. H. Yang, W. C. Hung et al., Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting, Am J Cardiol, vol.97, pp.192-196, 2006.

R. R. Azar, R. Kassab, A. Zoghbi, S. Aboujaoude, H. El-osta et al., Effects of clopidogrel on soluble CD40 ligand and on highsensitivity C-reactive protein in patients with stable coronary artery disease, Am Heart J, vol.151, issue.521, pp.1-4, 2006.

T. Cuisset, C. Grosdidier, A. D. Loundou, J. Quilici, M. Loosveld et al., Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs), JACC Cardiovasc Interv, vol.6, pp.854-63, 2013.

R. Mehran, S. V. Rao, D. L. Bhatt, C. M. Gibson, A. Caixeta et al., Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium, Circulation, vol.123, pp.2736-2783, 2011.

C. Grosdidier, J. Quilici, M. Loosveld, L. Camoin, P. J. Moro et al., Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications, Am J Cardiol, vol.111, pp.985-90, 2013.

M. Canault, D. Ghalloussi, C. Grosdidier, M. Guinier, C. Perret et al., Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding, J Exp Med, vol.211, pp.1349-62, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01478363

E. Von-elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gotzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies, Int J Surg, vol.12, pp.1495-1504, 2014.

S. Pehrsson, K. Hansson, K. Nelander, and S. Nylander, Boosting the coagulation restores haemostasis in ticagrelor-treated mice, Blood Coagul Fibrinolysis, vol.27, pp.913-922, 2016.

M. J. Kuijpers, N. J. Mattheij, L. Cipolla, J. P. Van-geffen, T. Lawrence et al., Platelet CD40L modulates thrombus growth via phosphatidylinositol 3-kinase beta, and not via CD40 and IkappaB kinase alpha, Arterioscler Thromb Vasc Biol, vol.35, pp.1374-81, 2015.

N. Varo, D. Vicent, P. Libby, R. Nuzzo, A. L. Calle-pascual et al., Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones, Circulation, vol.107, pp.2664-2673, 2003.

J. Huang, C. Jochems, T. Talaie, A. Anderson, A. Jales et al., Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role, Blood, vol.120, pp.3030-3038, 2012.

F. N. Gavins, G. Li, J. Russell, M. Perretti, and D. N. Granger, Microvascular thrombosis and CD40/CD40L signaling, J Thromb Haemost, vol.9, pp.574-81, 2011.

U. R. Schwarz, A. L. Kobsar, M. Koksch, U. Walter, and M. Eigenthaler, Inhibition of agonist-induced p42 and p38 mitogen-activated protein kinase phosphorylation and CD40 ligand/P-selectin expression by cyclic nucleotide-regulated pathways in human platelets, Biochem Pharmacol, vol.60, pp.1399-407, 2000.

H. Van-nispen-tot-pannerden, F. De-haas, W. Geerts, G. Posthuma, S. Van-dijk et al., The platelet interior revisited: electron tomography reveals tubular alpha-granule subtypes, Blood, vol.116, pp.1147-56, 2010.

D. Jonnalagadda, L. T. Izu, and S. W. Whiteheart, Platelet secretion is kinetically heterogeneous in an agonist-responsive manner, Blood, vol.120, pp.5209-5225, 2012.

J. Dechanet, C. Grosset, J. L. Taupin, P. Merville, J. Banchereau et al., CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells, J Immunol, vol.159, pp.5640-5647, 1997.
URL : https://hal.archives-ouvertes.fr/inserm-02519470

S. Giannini, E. Falcinelli, L. Bury, G. Guglielmini, R. Rossi et al., Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake, Am J Physiol Heart Circ Physiol, vol.300, pp.2072-2081, 2011.

V. Henn, J. R. Slupsky, M. Grafe, I. Anagnostopoulos, R. Forster et al., CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells, Nature, vol.391, pp.591-595, 1998.

G. Zuchtriegel, B. Uhl, D. Puhr-westerheide, M. Pornbacher, K. Lauber et al., Platelets guide leukocytes to their sites of extravasation, PLoS Biol, vol.14, p.1002459, 2016.